Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Apple Dethrones Nvidia as KOSPI Crashes 11%, Oil Drops on Iran Pause and Warsh's Fed Begins a Two-Day Meeting: 7 Reads Before Tuesday's Bell

WTI crude trades at $81.47 (-1.38%) and Brent at $86.99 (-1.55%) pre-market, both down more than 2% as investors price a pause in U.S.-Iran hostilities. Trump said America was "having good talks" with Iran but warned he would resume strikes if negotiations collapse. Iran-backed …

Nitish Kishor | 28 July 2026

Centene Corporation (NYSE:CNC) Jumps 2% Pre-Market Today on Strong Q2 Earnings Beat

Centene Corporation (NYSE:CNC) shares jumped in pre-market trading on Tuesday after the company delivered a sharp second-quarter earnings beat, with adjusted earnings per share of $2.51 crushing analyst estimates of roughly $1.08 and revenue of $53.58 billion topping consensus of about $47.6 billion.

Nitish Kishor | 28 July 2026

IQVIA Holdings (NYSE:IQV) Jumps 8% Pre-Market Today on Q2 Beat and Raised Guidance

IQVIA Holdings (NYSE:IQV) shares surged in pre-market trading on Tuesday after the company reported second-quarter results that topped Wall Street estimates on both the top and bottom lines. Adjusted earnings per share of $3.15 beat a consensus estimate of $3.03, while revenue of $4.37 …

Nitish Kishor | 28 July 2026

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surges 12% Pre-Market Today on Q2 Beat and Raised Guidance

Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares surged in pre-market trading on Tuesday after the company reported second-quarter results that beat Wall Street estimates on both earnings and revenue, with adjusted earnings per share of $0.30 topping a consensus estimate of $0.27 to $0.28 and revenue of …

Nitish Kishor | 28 July 2026

Why Is Neumora Therapeutics (NASDAQ:NMRA) Slightly Lower Pre-Market Today?

Neumora Therapeutics (NASDAQ:NMRA) shares ticked down modestly in pre-market trading on Tuesday, pulling back slightly after a sharp 11.41 percent surge in the prior session that followed favorable repeat toxicology results for NMRA-215, the company's brain-penetrant oral NLRP3 inhibitor being developed for obesity and …

Nitish Kishor | 28 July 2026

OPKO Health (NASDAQ:OPK) Rises 6% Pre-Market Today Despite Lukewarm Analyst Ratings

OPKO Health (NASDAQ:OPK) shares climbed in pre-market trading on Tuesday after the company reported a narrower-than-expected second-quarter loss following its earnings release after Monday's close. The company posted a net loss of $0.01 per share, versus consensus estimates of a $0.08 loss, on revenue …

Nitish Kishor | 28 July 2026

Scribe Therapeutics (NASDAQ:SCTX) Ticks Up Pre-Market Today After Steep Post-IPO Decline

Scribe Therapeutics (NASDAQ:SCTX) shares ticked higher in pre-market trading on Tuesday, recovering slightly after falling 13.77 percent in Monday's session, just days after the company's initial public offering on the Nasdaq Global Market. The stock priced at $15.00 per share on July 24, with …

Nitish Kishor | 28 July 2026

Managed Care Stocks Gain as UnitedHealth Group (NYSE:UNH) Edges Higher Pre-Market Today

UnitedHealth Group (NYSE:UNH) shares edged higher in pre-market trading on Tuesday, tracking broader strength across managed-care and health insurance peers after Centene (NYSE:CNC) reported a strong second-quarter beat with net income surpassing $1 billion and improved health benefits ratios, easing sector-wide concerns about medical …

Nitish Kishor | 28 July 2026

Zillow Group (NASDAQ:Z) Ticks Higher Despite Ongoing Securities Litigation Overhang

Zillow Group (NASDAQ:Z) shares traded higher in pre-market action on Tuesday, extending a modest rebound after the stock touched levels near its 52-week low. The move comes as investors weigh multiple headline-driven pressures against early signs of stabilization, with shares remaining well below both …

Nitish Kishor | 28 July 2026

AbbVie (NYSE:ABBV) Rises Pre-Market Today After Barclays Price Target Hike

AbbVie (NYSE:ABBV) shares traded higher in pre-market action on Tuesday after Barclays raised its price target on the stock to $300 from $275 while maintaining an Overweight rating. The upgrade adds to bullish analyst sentiment following the company's recently completed acquisition of Apogee Therapeutics.

Nitish Kishor | 28 July 2026
Support

Hi! How can we help you today?

Loading…